AstraZeneca Boosts Cancer Portfolio With $320 Million Neogene Deal
AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday, seeking to build its pipeline of cell-based cancer treatments.
Reuters Health Information
source https://www.medscape.com/viewarticle/984703?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/984703?src=rss
Comments
Post a Comment